Allara Health, MD-Led Platform

Allara Health is a New York-based telehealth platform founded in 2019 with a specific focus on hormonal and metabolic conditions that have historically been underdiagnosed and undertreated in women — most notably polycystic ovary syndrome (PCOS). The company launched with the premise that PCOS, which affects an estimated 1 in 10 women of reproductive age, often takes years to diagnose and receives fragmented care across OB/GYNs, endocrinologists, and primary care physicians who rarely coordinate. Allara's model attempts to solve this by assembling an integrated virtual care team for each patient. The platform pairs every patient with a board-certified medical provider — drawn from OB/GYNs, endocrinologists, and women's health nurse practitioners — alongside a registered dietitian who works as a co-equal member of the care team. This dual-provider model is clinically meaningful for PCOS patients because the condition has substantial dietary and metabolic dimensions that cannot be addressed through prescription medication alone. Research consistently shows that insulin resistance, which underlies many PCOS symptoms, responds significantly to dietary interventions, and Allara's dietitians are trained specifically in hormonal and metabolic health rather than general nutrition counseling. Beyond PCOS, Allara treats insulin resistance, endometriosis, Hashimoto's thyroiditis, hypothyroidism, primary ovarian insufficiency, PMDD, uterine fibroids, and perimenopause. This breadth distinguishes it from single-condition platforms while keeping the clinical focus on hormonal and metabolic root causes rather than symptomatic care. In January 2025, Allara raised a $26 million Series B round to accelerate national expansion and insurance contracting. The company has since expanded to serve patients in all 50 states and has established in-network partnerships with Aetna, Cigna, Blue Cross Blue Shield, Humana, and United Healthcare — an unusual insurance footprint for a women's telehealth startup, which has historically struggled to secure payer contracts. In a 2025 patient outcome survey, 70% of Allara patients with irregular periods reported improved menstrual regularity, and two-thirds of prediabetic patients normalized their A1C within 10 months. The company reports serving more than 40,000 women nationally. For patients who have cycled through conventional medicine without clear answers on hormonal symptoms, Allara represents a meaningfully different experience: one in which the care team is specifically trained in hormonal conditions, has the time to investigate root causes, and coordinates longitudinal care rather than treating each visit in isolation. The company launched with the premise that PCOS, which affects an estimated 1 in 10 women of reproductive age, often takes years to diagnose and receives fragmented care across OB/GYNs, endocrinologists, and primary care physicians who rarely coordinate. Allara's model attempts to solve this by assembling an integrated virtual care team for each patient. The platform pairs every patient with a board-certified medical provider — drawn from OB/GYNs, endocrinologists, and women's health nurse practitioners — alongside a registered dietitian who works as a co-equal member of the care team. This dual-provider model is clinically meaningful for PCOS patients because the condition has substantial dietary and metabolic dimensions that cannot be addressed through prescription medication alone. Research consistently shows that insulin resistance, which underlies many PCOS symptoms, responds significantly to dietary interventions, and Allara's dietitians are trained specifically in hormonal and metabolic health rather than general nutrition counseling. Beyond PCOS, Allara treats insulin resistance, endometriosis, Hashimoto's thyroiditis, hypothyroidism, primary ovarian insufficiency, PMDD, uterine fibroids, and perimenopause. This breadth distinguishes it from single-condition platforms while keeping the clinical focus on hormonal and metabolic root causes rather than symptomatic care. In January 2025, Allara raised a $26 million Series B round to accelerate national expansion and insurance contracting. The company has since expanded to serve patients in all 50 states and has established in-network partnerships with Aetna, Cigna, Blue Cross Blue Shield, Humana, and United Healthcare — an unusual insurance footprint for a women's telehealth startup, which has historically struggled to secure payer contracts. In a 2025 patient outcome survey, 70% of Allara patients with irregular periods reported improved menstrual regularity, and two-thirds of prediabetic patients normalized their A1C within 10 months. The company reports serving more than 40,000 women nationally. For patients who have cycled through conventional medicine without clear answers on hormonal symptoms, Allara represents a meaningfully different experience: one in which the care team is specifically trained in hormonal conditions, has the time to investigate root causes, and coordinates longitudinal care rather than treating each visit in isolation.